Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mashail Manzur

Podiatrist Tucker, GA Doctor of Podiatric Medicine

NPI 1689107807 CMS profile 5692066

1460 Montreal Rd E, Ste 250, Tucker, GA 30084

Open in the dashboard

General payments

$6,663

74 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mashail Manzur of Tucker, GA is reported in the CMS Open Payments database as having received $6,663 across 74 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $25 1
2024 General $67 2
2023 General $183 4
2022 General $128 6
2021 General $81 5
2020 General $1,200 17
2019 General $4,978 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mashail Manzur
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Mashail Manzur were reported at $25. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Mashail Manzur Podiatrist median Middle half National median
2019 $4,978 $196 $72–$601 $163
2020 $1,200 $118 $38–$335 $114
2021 $81 $169 $57–$573 $132
2022 $128 $220 $74–$782 $149
2023 $183 $208 $71–$635 $160
2024 $67 $237 $87–$681 $164
2025 $25 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $2,645 37 payments
  2. Southern Edge Orthopaedics, Inc. $1,844 1 payment
  3. Amniox Medical, Inc. $784 8 payments
  4. TissueTech, Inc. $356 2 payments
  5. Medical Device Business Services, Inc. $320 2 payments
  6. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $144 3 payments
  7. Organogenesis Inc. $91 1 payment
  8. KCI USA, Inc $81 2 payments
  9. Baxter Healthcare $64 2 payments
  10. Pfizer Inc. $54 1 payment
  11. Other $280 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,964 63 payments
  2. Education $2,164 3 payments
  3. Travel and Lodging $1,389 6 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $91 1 payment
  5. Consulting Fee $57 1 payment
Products named General payments · program years 2019–2025
  1. ANCHORAGE $2,035 26 payments
  2. NEOX $784 8 payments
  3. CLARIX $784 8 payments
  4. STAR $648 2 payments
  5. HOFFMANN $625 2 payments
  6. Prokera $356 2 payments
  7. AmnioGraft $356 2 payments
  8. AmnioGuard $356 2 payments
  9. ASNIS $243 4 payments
  10. ALLOGRAFT $171 1 payment
  11. Other $1,303 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

296

Median for Podiatry: 160

Drug cost

$5,366

Median for Podiatry: $2,368

Branded share of claims

19.9%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 79 $2,143
Ciclopirox Generic 72 $2,018
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 59 $971
Methylprednisolone Generic 24 $102
Meloxicam Generic 49 $78
Gabapentin Generic 13 $54

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$42,700

Medicare's payments for the services billed

Medicare patients

155

Average age 77

Services billed

640

90 women, 65 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 45%
Chronic kidney disease 43%
Ischemic heart disease 34%
Atrial fibrillation 30%
Heart failure 26%
Depression 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

74 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record